<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Torus Biosystems — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>
<header class="site-header"><h1>Prospect Detail</h1></header>
<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Diagnostics</span>
    <h1>134. Torus Biosystems</h1>
    <p class="meta">Point-of-Care Diagnostics in Under 30 Minutes</p>
  </div>
  <div class="section"><h3>1. Startup Name</h3><p><strong>Torus Biosystems</strong></p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Tell me more about this company's origin story...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>2. Founder Contact</h3><p><strong>Peng Yin & David Zhang</strong></p><p>Wyss Institute</p><p>Dr. Yin is a leader in DNA nanotechnology and programmable molecular systems; pioneering work in isothermal amplification for diagnostics</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Research the founder's background and credentials...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>3. Product Overview</h3><p>Torus Biosystems develops rapid point-of-care molecular diagnostics that deliver PCR-quality results in under 30 minutes. Using proprietary isothermal amplification technology developed at the Wyss Institute, Torus enables highly accurate diagnostic testing outside traditional laboratory settings — in clinics, pharmacies, and at-home. The platform addresses the critical gap between slow lab-based PCR and less accurate rapid antigen tests.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What competitors does this product face?">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>4. Funding Stage</h3><p><strong>Series A — $25M</strong> — Advancing development and commercialization of rapid point-of-care diagnostic platform.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What's the typical next funding milestone?">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>5. How I Found the Company</h3><p>Discovered through Wyss Institute portfolio research and point-of-care diagnostics innovation landscape.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Find more recent news about this company...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="strengths-weaknesses">
    <div class="section"><h3>Strengths</h3><ul><li><strong>Speed + accuracy:</strong> Combines PCR-level accuracy with rapid 30-minute turnaround at point-of-care.</li><li><strong>Wyss pedigree:</strong> Technology developed by leading DNA nanotechnology researchers.</li><li><strong>Market timing:</strong> COVID highlighted need for fast, accurate decentralized testing.</li></ul>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Validate these strengths with market data...">
        <button>Ask AI</button>
      </div>
    </div>
    </div>
    <div class="section"><h3>Weaknesses</h3><ul><li><strong>Crowded space:</strong> Many players pursuing rapid molecular diagnostics post-COVID.</li><li><strong>Regulatory pathway:</strong> FDA clearance for new diagnostic platforms is rigorous and time-consuming.</li></ul>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What other risks should I consider?">
        <button>Ask AI</button>
      </div>
    </div>
    </div>
  </div>
  <div class="section"><h3>7. Five Questions for the Team</h3><ol class="questions-list"><li>What is your FDA regulatory timeline and strategy?</li><li>Which disease areas are you initially targeting — infectious disease, STIs, respiratory?</li><li>How does your cost-per-test compare to existing rapid molecular tests like Abbott ID NOW?</li><li>What is your hardware vs. consumables business model split?</li><li>Are you pursuing CLIA-waived status for true point-of-care deployment?</li></ol>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Generate additional due diligence questions...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section email-draft">
    <h3>8. Draft Outreach Email</h3>
    <div class="email-box">
      <p><strong>Subject:</strong> Harvard Undergraduate Capital Partners — Rapid Diagnostics from Wyss</p>
      <p>Dear Torus Biosystems Team,</p>
      <p>I'm reaching out from <strong>Harvard Undergraduate Capital Partners (HUCP)</strong>, a student-run investment group at Harvard focused on early-stage ventures led by Harvard-affiliated founders.</p>
      <p>We've been following Torus Biosystems's work on rapid point-of-care molecular diagnostics with great interest. The ability to deliver PCR-quality results in under 30 minutes addresses a critical gap in diagnostic testing that COVID made painfully clear. Dr. Yin's pioneering DNA nanotechnology work at the Wyss Institute provides a strong scientific foundation.</p>
      <p>As you advance through Series A development, would anyone on the team be open to a brief conversation? We'd love to learn more about your path from Wyss research to commercial diagnostics.</p>
      <p>Thank you for your time.</p>
      <p>Best,<br>[Your Name]<br>Harvard Undergraduate Capital Partners</p>
    </div>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Personalize this email with more specific details...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>
<script src="script.js?v=4"></script>
</body>
</html>
